A new GLP-1 tablet helped people with type 2 diabetes lose more weight than oral semaglutide.
Patients lost up to 8% of their body weight during the one-year study.
Eli Lilly developed the drug orforglipron.
It lowers blood sugar, slows digestion, and reduces appetite.
Patients can take it without fasting.
More than 1,500 adults joined the global phase 3 trial.
Orforglipron also reduced average blood sugar more strongly than semaglutide.
However, more participants stopped treatment because of stomach-related side effects.
Experts see major potential for simple, low-cost tablet therapies.
They stress the need for longer studies on safety and heart health.
Researchers expect powerful weight-loss pills to reshape type 2 diabetes care within the next decade.
